David M. Aboulafia
Highly rated in
Highly rated in
Check Dr. David M. Aboulafia's experience treating your condition:
About Dr. David M. Aboulafia

David Aboulafia is a Hematologist Oncology expert in Seattle, Washington. Aboulafia has been practicing medicine for over 39 years and is highly rated in 45 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Kaposi Sarcoma, B-Cell Lymphoma, and Diffuse Large B-Cell Lymphoma DLBCL. He is licensed to treat patients in Washington. Aboulafia is currently accepting new patients.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 19 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. David M. Aboulafia it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. David M. Aboulafia accepts the following insurance:

  •  Ambetter
  •  PacificSource

Call to see if your plan is accepted.
1100 9th Ave, Seattle, WA 98101
Background & Education
Graduate Institution
University Of Michigan Medical School, 1983
Hematology Oncology
Internal Medicine in WA
Hospital Affiliations
Virginia Mason Seattle Medical Center
Olympic Medical Center
Yakima Valley Memorial
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma
Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
View 13 Less Clinical Trials -

83 Total Publications

Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer.

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors